Two Sigma Securities
BIB icon

Two Sigma Securities’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Two Sigma Securities’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,461
Closed -$243K – 1556
2021
Q2 		$243K Buy
+2,461
New +$215K 0.01% 1147
2017
Q3 		– Sell
-5,559
Closed -$297K – 931
2017
Q2 		$297K Buy
+5,559
New +$271K 0.06% 366
2016
Q3 		– Sell
-5,365
Closed -$208K – 660
2016
Q2 		$208K Buy
+5,365
New +$231K 0.11% 258

Other funds holding BIB

Howard Capital Management
Howard Capital Management Roswell, Georgia $8.26B AUM 36.73% 1-Year Est. Return
Geneos Wealth Management
Geneos Wealth Management Englewood, Colorado $5.32B AUM 16.49% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Old Mission Capital
Old Mission Capital Chicago, Illinois $6.31B AUM 20.8% 1-Year Est. Return
Chase Investment Counsel
Chase Investment Counsel Charlottesville, Virginia $479M AUM 81.51% 1-Year Est. Return
Toth Financial Advisory
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
Capital Investment Advisors
Capital Investment Advisors Atlanta, Georgia $7.74B AUM 15.52% 1-Year Est. Return
Orion Portfolio Solutions
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UMC
United Maritime Capital New York $15.2M AUM 45.42% 1-Year Est. Return

Two Sigma Securities's BIB Position: Q3 2021 in Review

Two Sigma Securities sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2021, closing a stake of 2,461 shares — an estimated $243K sold.

Two Sigma Securities first reported a position in BIB in Q2 2016 and held it in 3 quarters. The position peaked at $297K in Q2 2017. 32 funds tracked by Wall St. Rank hold BIB as of Q3 2021.

  • Two Sigma Securities reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2021 after selling out during the quarter.
  • Two Sigma Securities sold 2,461 ProShares Ultra NASDAQ Biotechnology shares in Q3 2021, an estimated $243K.
  • Two Sigma Securities first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2016 and held it in 3 quarters.
  • Two Sigma Securities's ProShares Ultra NASDAQ Biotechnology position peaked at $297K in Q2 2017.
  • 32 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2021.

Based on Two Sigma Securities's 13F filing for Q3 2021, filed 15 Nov 2021.